Clinical trial
Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to…
NCT00244192 · Center for Integrated Rehabilitation and Organ Failure Horn, Other · Completed
Key facts
| NCT number | NCT00244192 |
|---|---|
| Title | Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia |
| Lead sponsor | Center for Integrated Rehabilitation and Organ Failure Horn, Other |
| Collaborators | Centocor, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | COPD, Cachexia |
| Intervention type | Drug |
| Interventions | infliximab (Remicade) |
| Enrollment | 16 |
| Start date | Oct 1, 2003 |
| Completion | Dec 1, 2005 |
| First posted | Oct 26, 2005 |
| Last update posted | Dec 9, 2005 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: